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Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely
understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number
profiling and cytogenetics to analyse 84 myeloma samples. Most cases have a complex
subclonal structure and show clusters of subclonal variants, including subclonal driver
mutations. Serial sampling reveals diverse patterns of clonal evolution, including linear evo-
lution, differential clonal response and branching evolution. Diverse processes contribute to
the mutational repertoire, including kataegis and somatic hypermutation, and their relative
contribution changes over time. We find heterogeneity of mutational spectrum across
samples, with few recurrent genes. We identify new candidate genes, including truncations of
SP140, LTB, ROBO1 and clustered missense mutations in EGR1. The myeloma genome is
heterogeneous across the cohort, and exhibits diversity in clonal admixture and in dynamics
of evolution, which may impact prognostic stratification, therapeutic approaches and
assessment of disease response to treatment.
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M
ultiple myeloma (MM) is a malignant monoclonal
plasma cell disorder whose pathogenesis is only
partially understood. MM is classically subdivided into
subtypes with rearrangements involving the immunoglobulin
heavy (IGH) locus and a hyperdiploid subtype, which harbours
multiple trisomies1. These chromosomal abnormalities are,
however, insufficient for malignant transformation, as they are
also observed in monoclonal gammopathy of unknown
significance, a premalignant syndrome that precedes virtually
every MM case2,3. MM undergoes a multistep transformation
process and its genetic landscape changes over time due to
additional events such as somatic mutations, epigenetic and
chromosomal copy-number changes driving its progression from
monoclonal gammopathy of unknown significance to
symptomatic MM and ultimately to aggressive extramedullary
disease in some patients4. Sequencing efforts in relatively small
cohorts of MM samples have already been undertaken, suggesting
that MM show a heterogeneous subclonal structure at diagnosis
and only few recurrent mutated genes of likely patho-
genetic significance, including KRAS, NRAS, TP53, BRAF
and FAM46C 5–8. Interestingly, single nucleotide polymorphism
(SNP) arrays on serial samples showed that molecular events
necessary for MM progression are not attained in a linear fashion
but rather through branching, nonlinear pathways9,10, a pattern
typical of a complex ecosystem of clones competing for evolution.
The quantitative nature of next generation sequencing (NGS)
data allows for higher resolution of the subclonal architecture of
cancers11 and its monitoring over time with implication for
prognostic stratification, tumour monitoring and emergence of
chemoresistance12,13. Nevertheless, initial reports of genomic
evolution in MM using NGS were conducted again on small
cohorts6,8, thus limiting their relevance to the broadly
heterogeneous spectrum of myeloma samples. Importantly,
NGS data can also be used to decipher mutational signatures, a
combination of mutated nucleotides in a specific context that can
inform about mutational processes operative in each cancer and
thus offer a mechanistic explanation for the mutations found in
the sample14. Recent reports suggested that different processes are
operative in MM15–17, but their relative representation in each
sample, the dynamics of their contribution over time and their
relation to clinical features are unknown.
Here we show the largest cohort to date of MM patients where
we combine cytogenetic, copy number and whole-exome-
sequencing analysis. We show that most patients have a complex
subclonal structure at diagnosis, which evolves further after
treatment in the majority of them. We identify mutational
processes leading to the generation of MM heterogeneous
mutational repertoire, and how they dynamically evolve over
time. We describe new candidate driver gene mutations that
could inform about disease pathogenesis and prognosis.
Results
Landscape of genetic alterations in MM. We analysed 84
samples from 67 patients with MM using exome sequencing,
high-resolution copy-number arrays and cytogenetics
(Supplementary Tables S1 and S2). For 52 patients, one sample
was available (pretreatment in 51 cases). We collected serial
samples in 15 patients, starting at disease progression or relapse
post treatment in 14 of them, with later time points always col-
lected at relapse/progression after further lines of treatment
(Table 1). The median interval between samples was 299 days
(range 77–618, Supplementary Table S1).
Exome sequencing, performed at a total average depth of
236 (Supplementary Table S3), allowed us to identify and
validate 4,417 variants (range 21–488, median 52 per patient)
(Fig. 1a, Supplementary Data 1). Non-silent coding variants (that
is, missense, nonsense, indel, splice) were enriched over silent
ones (that is, synonymous, intronic, untranslated region)
(Fig. 1b). Ranking by mutation type showed an excess of C4T
transitions (Fig. 1c). We identified 183 homozygous deletions
totalling 35.4Mb (Supplementary Data 2).
From copy-number data, 40/67 patients harboured a hyperdi-
ploid karyotype (Supplementary Table S2). Fluorescence in situ
hybridization (FISH) analysis showed 15/67 patients were
positive for IGH rearrangements: 6/67 for t(4;14), with increased
expression of FGFR3 and MM SET domain; 7/67 for t(11;14),
with consequent upregulation of cyclin D1; and 2/67 for t(14;16),
involving C-maf. Two hyperdiploid samples also carried a sub-
clonal t(11;14) translocation by FISH (Supplementary Table S2).
In 12 patients, FISH on IGH rearrangements other than t(4;14)
was not available. Other copy-number alterations such as del(1p),
(þ 1q), del(12p), del(13), del(14q), del(16q), del(17p) were found
in both hyperdiploid and IGH rearranged cases.
The combination of whole-exome sequencing, FISH and copy-
number analysis provided an integrated snapshot of the complex-
ity of alterations affecting the myeloma coding genome. Overall,
the detection of such a large burden of somatic variants and copy-
number alterations, with high variability across the 67 individuals
studied, indicates that the genetic landscape of myeloma is
remarkably heterogeneous and that largely distinct sets of
chromosomal rearrangements and gene mutations are present
in individual patients.
Modelling clonal and subclonal mutation clusters. Cancer
evolves through a Darwinian process of clonal expansion, and the
population of cancer cells represents an admixture of competing
subclones. We explored the clonal structure of our cohort using
SNP arrays and whole-exome sequencing data to identify sub-
clonal copy-number changes, simultaneously estimating and
adjusting for tumour ploidy and normal cell contamination. A
number of cases showed subclonal gains or losses of large-scale
genomic regions (examples shown in Supplementary Fig. S1A). A
similar analysis was carried out for point mutations by calculating
the 95% confidence interval for the fraction of tumour cells
carrying each mutation (again adjusting for the percentage of
contaminating normal cells of the sample and the copy number of
the locus). Each mutation was classified as clonal (that is, present
Table 1 | Disease status at the time of sampling.
Timepoint 1st 2nd 3rd
Treatment Pre Post Pre Post Pre Post Total
Patients with one time point 51 1 NA NA NA NA 52
Patients with two time points 1 12 0 13 NA NA 26
Patients with three time points 0 2 0 2 0 2 6
Total 52 15 0 15 0 2 84
For each group of patients (that is, those with one sample only, and those with two and three serial samples), the number of samples are plotted in relation to treatment received before sampling.
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in all tumour cells) if the upper bound of the 95% confidence
interval included 1, and subclonal otherwise. We plotted, for each
patient, the absolute number and proportion of clonal and sub-
clonal variants and showed that almost every patient carries
variants present in a fraction of tumour cells, implying ongoing
tumour evolution at the time of sampling (Fig. 2a). We then
clustered the fraction of tumour cells carrying each mutation
using a Bayesian Dirichlet process, to reflect the clonal compo-
sition of the tumour. We showed that all patients carry a cluster
of variants that are clonal (that is, at 1.0 on the x axis in Fig. 2b–d,
Supplementary Fig. S1B). Rarely, patients had only few subclonal
variants and no significant clustering at the subclonal level
(Fig. 2b), whereas most patients showed a major cluster of clonal
mutations and one or more clusters of subclonal variants (Fig. 2c,
Supplementary Fig. S1B). Interestingly, few patients had many
more subclonal mutations than clonal, in several clusters
(Fig. 2d), indicating a complex dynamic of tumour evolution
from the most recent common ancestor—the most recent tumor
cell that has the full complement of somatic mutations found in
all tumour cells—through acquisition of new variants in different
subclones.
We next turned our attention to substitutions in known driver
genes in myeloma5–7. Interestingly, for each of the known driver
genes in myeloma (KRAS, NRAS, BRAF), we found both patients
in whom the mutations were clonal and patients in whom they
were subclonal (Fig. 2e). Therefore, even variants with known
driver potential can be acquired late in myeloma evolution,
implying striking variability across patients as to which are early
molecular events and which arise later during tumour
progression. Another layer of complexity arose in 5/67 samples
that surprisingly showed overlap of two or more driver
substitutions in KRAS, NRAS or BRAF (Fig. 2e, patient IDs in
red). In PD5878, it can be concluded that KRAS and BRAF both
coexisted in the main clone of the tumour, and were therefore
both present in all tumour cells. In PD4289, KRAS was present in
all tumour cells, while a subclone of cells containing a BRAF
mutation evolved later. In other cases, both variants were present
at the subclonal level, making it impossible to resolve whether
they belong to the same or different clones. If they
were in different clones, this would be suggestive of convergent
evolution, that is, two different subclones independently
acquiring mutations activating the same pathway, as reported
in ALL18, pancreatic cancer19 and renal cancer20.
Clonal evolution. We next analysed cases with serial samples.
Through analysis of the copy-number patterns, we could track
clonal evolution in large-scale genomic aberrations over time
(Fig. 3a–d). We also clustered point mutations based on clonality
again using a Bayesian Dirichlet process, extended into two
dimensions to give insights of the changes in the clonal compo-
sition of each tumour over time. We plotted the fraction of
tumour cells harbouring each variant on the x axis for the ‘early’
sample, and on the y axis for the ‘late’ sample (Fig. 3ai–di;
Supplementary Fig. S2A). We observed four major patterns in
these paired samples, instructive of genomic evolution over time
and possibly across sampling sites21.
In the first pattern we observed, in 5/15 patients, the various
clonal and subclonal clusters were found on the leading diagonal
of the plots (Fig. 3ai) suggesting there was no change in either the
mutational profile or the clonal and subclonal composition
between the two time points (Fig. 3aii). This is rather remarkable,
given that these five patients were all treated between the early
and late samples, and indeed some had a substantial response as
measured by paraprotein levels (Supplementary Table S1). The
lack of change in mutational composition suggests that various
subclones repopulating the myeloma at relapse were equivalently
affected (or unaffected) by treatment. Second, we observed
‘differential clonal response’ in the tumour, in which each
subclone was identified at the two time points, but their relative
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Figure 1 | Sequencing metrics of the study. (a) Total number of validated somatic variants for each patient in the cohort. (b) Breakdown of variants by type.
(c) Breakdown of variants by nucleotide change. Transitions (C4T, T4C) are in light blue, transversions (C4A, C4G, T4A, T4G) in dark blue.
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Figure 2 | Modelling clonal and subclonal mutation clusters. (a) Stacked bar chart showing the number of clonal mutations (present in all tumour cells,
light blue) and subclonal mutations (dark blue) in each patient. Also shown is the percentage of subclonal variants (orange triangles). For patients
with multiple samples, the fraction of tumour cells used was derived from the earliest sample where the mutation was found. (b–d) Statistical modelling by
a Bayesian Dirichlet process of the distribution of clonal and subclonal mutations for three patients for which only one sample was available. For each plot,
the faction of tumour cells carrying the variant is represented on the x axis (1¼ 100% of tumour cells), and the probability density (on an arbitrary scale) on
the y axis. Grey bars represent the histogram of mutations, with the fitted distribution as a dark purple line. The 95% posterior confidence intervals
for the fitted distribution are represented by a pale blue area. (b) Patient showing a vast majority of clonal variants; (c) patient with a dominant set of clonal
mutations and a minor subclone; (d) patient showing a dominant set of subclonal mutations, at two different proportions. (e) Adjusted fraction of
tumour cells carrying KRAS, NRAS and BRAF substitutions found in the study. Error bars represent 95% confidence intervals, accounting for chromosomal
copy number of the locus, percentage contaminating normal cells and depth of coverage. (Note that patient PD5883, carrying a BRAF indel, was not
included in this panel due to the inaccurate estimation of the allelic fraction of indels). All mutations whose confidence interval includes 1 (red line) are
considered to be present in all tumour cells with 95% confidence. Driver mutations can be found at the clonal or subclonal level, and sometimes coexist in
the same patient (Patient IDs in red). For patients with multiple samples, the fraction of tumour cells used was derived from the earliest sample
where the mutation was found. In three patients (PD5876, PD5885, PD5892), a fraction of B1.5 was assigned, likely due to focal subclonal gains of the
variant locus that went undetected by our algorithms, so that the estimated fraction of tumour cells was not adjusted.
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Figure 3 | Clonal evolution. (a–d) Chromosomal copy-number plots for the early and late sample; in each plot, purple¼ total copy number, blue¼ copy
number of the minor allele. (ai–di) Two-dimensional density plots showing the clustering of the fraction of tumour cells carrying each mutation (black dots)
at each time point; increasing intensity of red indicates the location of a high posterior probability of a cluster. (aii–dii) Phylograms representing
the clonal composition of the tumour at each timepoint, where the length of each branch is proportional to the size of the clone (that is, the number of
variants), and the width to its clonality (that is, the proportion of tumour cells bearing each variant). Grey circles represent the nodes of the phylograms,
that is, the point at which a separate group of cells diverges in evolution from the parental clone. The distance between nodes relates to the evolution time
from the fertilized egg down the trunk of the phylograms (that is, the main clone of the tumour), through the most recent common ancestor to the
branches of the phylogram (that is, the different subclones of the tumour arisen later in evolution). For each branch, the number and average clonality of the
variants has been annotated (black text), along with notable copy-number changes and mutations (dark blue text). (e) Pie chart breakdown of the
proportional representation of the different kinds of clonal evolution observed in the cohort. (f) Histograms showing the number of cases and type of
clonal evolution for each karyotypic subgroup.
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proportions changed over time (Fig. 3bi,ii). These changes might
reflect random drift of subclones over time, differential response
among subclones to chemotherapy or clonal expansion due to
selective advantage of one subclone over the others. This pattern
was found in 4/15 patients. Interestingly in PD4292, for which
three samples were available, we observed differential clonal
response in ‘early’ versus ‘late’ and ‘late versus later’ samples.
Nevertheless, the drift of subclones at the two intervals was in
opposite direction, so that there was actually no change between
the first and third sample (Supplementary Fig. S2A). This
illustrates how different subclones can show alternating dom-
inance over time, likely in this case influenced by treatment.
Third, we observed linear evolution in 2/15 patients, in which a
new subclone emerged in the late sample that was not evident
despite the deep sequencing in the earlier sample (Fig 3ci,ii).
Fourth, we found evidence of branching evolution in 4/15
patients (Fig. 3di,ii). Here, in the time between the early and late
time points, one or more new clones have emerged, whereas
others have declined in frequency or disappeared.
We found striking concordance between point mutations and
copy-number changes (Fig. 3a–d, Supplementary Fig. S2B), so
that karyotypic changes of prognostic value were only observed
between paired samples showing linear or branching evolution
(P¼ 0.0002, Fisher exact test). This concordance suggests that the
mutational processes acting at the level of point mutations and at
the level of aneuploidy in myeloma are broadly in concert over
time and across subclones.
Surprisingly, the pattern of genomic evolution could not be
predicted by response to treatment, interval between sampling or
treatment type. We noted that 4/5 cases with the t(11;14) trans-
location showed no change, as compared with only 1/9 in the
hyperdiploid group (P-value from Fisher test ¼ 0.023, Fig. 3f),
suggesting that cytogenetic subtypes can show different evolution
in response to treatment. Cases showing either branching
evolution or differential clonal response highlight how current
anti-myeloma treatment can have a differential effect across
subclones, suppressing some and leaving others untouched.
While this could have implications for the choice of treatment
modalities and for the definition of disease response, larger
sample sizes would be important to explore these points in more
detail. In our cohort of 15 patients with serial samples, we found
no differences in the survival based on the type of genomic
evolution shown at relapse.
Interestingly, the two most distinct examples of branching
evolution (PD4283 and PD4301) came from patients where the
late samples represented an extramedullary relapse of myeloma
(secondary plasma cell leukaemia and malignant ascites, respec-
tively). Not surprisingly, acquired variants in the late samples
included mutations in genes with known oncogenic potential in
MM. In the plasma cell leukemia sample, we found a TP53
mutation and a homozygous deletion of CDKN2C (Fig. 3di,ii). In
the ascites relapse, there were new clonal mutations in NRAS,
NFKBIA and FAM46C (Supplementary Fig. S2).
Finally, we looked at mutations in five known driver myeloma
genes (KRAS, NRAS, TP53, BRAF, FAM46C) across all patients
with serial samples, and identified 12 non-silent variants. Six out
of twelve were clonal at both time points. Of the remaining, 4/6
appeared in the late sample with no evidence in the early sample
despite high-sequence coverage, and 2/6 were subclonal at the
initial time point and increased their clonal fraction at the later
time point, consistent with the expected positive selection for the
subclones harbouring them (Supplementary Fig. S2C).
Different mutational processes active in MM. The catalogue of
somatic mutations in a cancer is the aggregate outcome of
strength and duration of exposure to one or more mutational
processes. Each process generates mutations characterized by a
specific combination of nucleotide change and nucleotide context,
therefore providing a ‘signature’ that can be used for its identifi-
cation. Because there are six classes of base substitution (that is,
C4A, C4T, C4G, T4A, T4C and T4G; all in pyrimidine
context) and 16 possible sequence contexts for each, there are 96
possible mutated trinucleotides, whose relative contribution we
represented as a heatmap for each case (Supplementary Fig. S3A).
We then employed a nonnegative matrix factorization (NMF) and
model selection approach to extract mutational signatures from all
cases22. Evaluation of NMF decompositions suggested that at least
two biologically distinct mutational signatures were present
(Fig. 4a). Each signature was characterized by a different profile
of the 96 potential trinucleotide mutations and contributed to a
different extent to each cancer. The most represented signature,
named Signature A (Fig. 4a), is a rather generic mutation signature
with enrichment of C4T transitions at CpG dinucleotides, an
intrinsic mutational process reflecting spontaneous deamination
of methylated cytosine to thymine. A similar signature is
dominant in myeloid malignancies23,24, a major contributor to
early mutations in breast cancer11,22 and seen at high rates in the
germline25. Potentially, other signatures operative in MM could be
admixed in Signature A, but larger studies will be required to
pursue this observation. A second signature, namely C4T, C4G
and C4A mutations in a TpC context (Signature B, Fig. 4b), was
the major contributor of mutations in a few samples (Fig. 4c). In
PD5863 and PD5874, the two patients with the highest overall
number of variants (Fig. 1a), virtually all of the mutational
repertoire could be attributed to Signature B. While mutations
attributed to Signature B were generally spread across the exome,
in two samples we found clusters of 4–6 cytosine mutations at
TpC dinucleotides within an interval of few hundred bp that also
showed strand specificity, indicative of a process known as
‘kataegis’22 (Supplementary Fig. S3B, arrows). Both the genome-
wide and the clustered variants of this mutational signature were
first documented in breast cancer11,22,26, and are hypothesized to
result from the aberrant activity of APOBECs, a family of proteins
that enzymatically modify single-stranded DNA27. While the
genome-wide variant of Signature B was recently described in
MM15,16, here we report the first evidence of clusters of kataegis in
this disease.
Kataegis was not the only process leading to regional clustering
of mutations in the cohort. We found clusters of mutations in the
first exon of CCND1 in two cases (Supplementary Fig. S3C,
arrows), both characterized by the t(11;14) translocation,
juxtaposing CCND1 with the IGH locus. Interestingly, selection
analysis of the mutations in CCND1 in our cohort revealed that
the observed mutations reflected a local mutation rate much
higher than the genomic average (Supplementary Table S4). The
breakpoints on 11q13 are dispersed over 330 kb centromeric to
CCND1 (ref. 28), and thus we do not believe that this could arise
from the proximity of CCND1 to the site of rearrangement.
Rather, the even representation of cytosine and adenine
mutations and the high synonymous to non-synonymous ratio
suggest CCND1 mutation clusters may result from somatic
hypermutation driven by the AID protein29,30, as previously
described for CCND1 itself in mantle cell lymphoma31 and for
BCL2 in follicular lymphomas32. We found that CCND1 was
significantly enriched for mutations in AID recognition motifs
(Supplementary Fig. S3C), further reinforcing this hypothesis.
Last, we analysed the contribution of each signature, over time
or across subclones, in seven patients where the number of
variants was high enough to allow a statistical analysis. We
observed a significant change in contribution from the two
signatures in 5/7 patients. In both cases of extramedullary relapse
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Figure 4 | Mutational processes operative in multiple myeloma. (a,b) Fraction of contribution of each mutation type at each context for the two
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showing branching evolution, the contribution from Signature B
increased significantly at relapse (Fig. 4d), and in PD4301d,
clustered in a pattern consistent with kataegis (Supplementary
Fig. S3Bi). Conversely, in the five other samples, we found that
the contribution of Signature B could either increase or decrease
over time or in different subclones (Supplementary Fig. S3D).
Overall, the representation of Signature B at relapse was not
predictive of the type of genomic evolution shown or of survival.
In summary, the MM genome is shaped by several different
mutational processes. These are likely to include spontaneous
deamination of methylated cytosine, kataegis and somatic
hypermutation. The scale of such mutational processes can vary
from genome wide to localized clusters of events, and frequently
changes over time. Further studies will be required to ascertain
whether the relative contribution of different mutational
processes can influence clinical outcome or can be influenced
by treatment.
Recurrently mutated genes in MM. We next analysed our data
set to identify genes that were mutated with a significant recur-
rence rate, and could therefore represent novel candidate driver
genes in MM. We applied a frequentist likelihood ratio test to
highlight genes with increased numbers of non-synonymous
substitutions and indels, relative to that expected for the synon-
ymous mutation rate. Through this algorithm, we found seven
genes recurrent with a high level of confidence (false discovery
rate (FDR)o0.10, asterisks in Fig. 5b). Mutations of genes
involved in the mitogen-activated protein kinase (MAPK)
pathway were the most prevalent (37/67 patients). Known KRAS
and/or NRAS-activating mutations were present in 32/67 patients.
BRAF mutations were present in 10/67 cases. While 9/10 BRAF
mutations were previously reported in the literature, only 3/10
were the classic V600E, an atypical feature compared with mel-
anoma or colorectal cancers. Other than these recurrently
mutated genes, we found occasional mutations in other genes
involved in MAPK signalling, such as NF1 and RASA2, a negative
regulator of RAS signalling33. Surprisingly, we again found
significant overlap, and two or more mutations activating the
MAPK pathway coexisted in 7/67 patients (Fig. 5b).
Thus, MAPK signalling is frequently activated in myeloma and
inhibition of this pathway could represent a valid therapeutic
target. We therefore examined the sensitivity of nine myeloma
cell lines, of which four carried BRAF or RAS mutations, to a
panel of BRAF and MEK inhibitors34. Among these lines, there
were no striking differences in IC50 attributable to genotype, nor
any general sensitivity of myeloma lines to these inhibitors
compared with other cancers (Supplementary Fig. S4). While the
number of lines examined is small, the pattern of response to
these inhibitors is similar to colorectal cancers with BRAF
mutations, which overcome BRAF inhibition by feedback
activation of other proliferative pathways35.
Another significant gene in our cohort is FAM46C, recently
confirmed to be a target of recurrent mutations in myeloma5,7,36.
We found eight patients carrying FAM46C mutations, statistically
associated with a hyperdiploid karyotype (P¼ 0.02, Fisher exact
test). While in the original reports the pattern of mutations was
rather hard to interpret, we find five truncating mutations, two
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in-frame indels and four missense mutations, three of which
clustered in amino acids 138–145 (Fig. 6). In patient PD5868, we
identified two truncating mutations, and in PD5891, we found
three missense mutations with different clonality. Unless all
mutations are in the same allele, this is suggestive of either
compound heterozygosity or convergent evolution in separate
subclones. Furthermore, patients PD5866 and PD5888 showed a
truncating mutation associated with deletion of the remaining
wild-type allele (Fig. 5a,b). The high rate of inactivating
mutations and gene deletions in our data clarifies that FAM46C
is a bona fide tumour-suppressor gene in MM37. TP53 mutations
were found in 10 patients, and were significantly enriched in cases
with del(17p) (P¼ 0.01, Fisher exact test). We also describe
additional genes mutated at a significant recurrence rate, and thus
novel candidate drivers in MM. SP140, a lymphoid-restricted
homologue of SP100 that encodes a nuclear body protein
implicated in antigen response of mature B cells38, showed four
truncating (2 frameshift, 1 nonsense, 1 splice site) and one
missense mutation (Fig. 6). LTB, a type II membrane protein of
the TNF family involved in lymphoid development, showed
clustered truncating mutations in three samples (Fig. 6), two of
which were associated with the loss of the wild-type allele
(Fig. 5b). LTB heterodimerizes with LTA to generate the ligand
for LTBR39, which is a positive regulator of the NF-kB pathway,
frequently amplified in MM40,41. This significant frequency of
inactivating somatic mutations suggests that SP140 and LTB are
novel candidate tumour suppressors in MM.
Using less stringent cutoffs (Po0.02 and FDR 40.10, see
‘Statistical analysis of recurrently mutated genes’ under Methods)
to identify novel genes involved in MM, we highlighted a number
of candidates (Supplementary Table S4). ROBO1, a transmem-
brane receptor implicated in beta-catenin and MET signalling
and recently reported as mutated in pancreatic cancer42, was
mutated in 5/67 patients. Strikingly, three of these mutations were
truncating, consistent with the copy-number loss seen in
pancreatic cancer (Fig. 6). The EGR1 gene, which encodes the
early growth response one transcription factor, carried four
missense mutations (Fig. 6), as well as being mutated in two
additional myeloma patients in the literature5. FAT3, a trans-
membrane protein belonging to the Cadherin superfamily43
showed a homozygous deletion, one nonsense and three
missense mutations (Fig. 6). Looking at genes targeted by both
mutations and copy-number variations, we highlighted TGDS, a
gene encoding enzyme involved in nucleotide sugars
metabolism44 located in chromosome 13, and SNX7, a member
of the sorting nexin family involved in intracellular trafficking45
located in 1p21.3. Both genes reside in commonly deleted
regions in myeloma, and both showed two truncating and one
missense mutations associated with loss of the WT allele
(Fig. 5a,b). Finally, we found a cluster of mutations involving
two neighbouring paternally imprinted genes that share
transcriptional regulation46 in 6/67 patients. PEG3, a gene
involved in NF-kB/TNF signalling47, and USP29, a poorly
characterized deubiquitinating enzyme involved in p53
stabilization48, showed a total of three nonsense and three
missense mutations, suggesting this locus could be a recurrent
target of mutations in MM (Fig. 6).
Manual inspection of the gene list allowed the identification of
several mutations in other genes previously implicated in
lymphoid malignancies, although at a non-significant recurrence
rate (Fig. 5b). Across our 67 patients, we find a missense variant
affecting the ankyrin repeat domain in NFKB1 and two
truncating somatic mutations each in NFKBIA, CYLD and
TRAF3. These data confirm that the non-canonical NF-kB
pathway is an important target for somatic mutation in MM41.
We also find somatic mutations in genes involved in B-cell
development, such as a nonsense mutation in RAG2 (deleted in
ALL) and a frameshift mutation in CD79A (mutated in diffuse
large B-cell lymphoma). Rare mutations were also found in other
cancer genes, including SF3B1 (three missense mutations in two
patients); ARID2 (one frameshift, one missense); PIK3CA (two
recurrent missense mutations); PTEN (one nonsense); KDM6A
(one homozygous deletion); CDK4 (one missense); CDKN2C
(one frameshift, one homozygous deletion); and SETD2 (one
nonsense).
In four patients, RNA-seq data were available, and we
confirmed that most of the known and candidate driver genes
in myeloma are expressed in the tumour cells, although at
variable levels (Supplementary Fig. S5A). In seven additional
patients, RNA was available for RT–PCR. We showed that
eight out of the 10 mutations we investigated were expressed,
suggesting good correlation between DNA mutational status and
expression of mutated driver genes (Supplementary Fig. S5B).
Interestingly, a nonsense mutation in the paternally imprinted
gene PEG3 showed a homozygous-mutated peak, confirming
hemizygous expression of the mutated allele and predicting loss
of function of the locus (Supplementary Fig. S5B, panel 9).
Relapse-free (Supplementary Fig. S6A–F) and overall survival
data (Supplementary Fig. S6Ai–Fi) were available for the 51
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patients sampled at diagnosis. We found, as previously reported1,
that hyperdiploid cases had longer overall survival than those
with IGH translocations (Supplementary Fig. S6Fi). We found no
significant difference in overall and relapse-free survival between
cases with mutations in KRAS, NRAS or BRAF compared with
those without. Similarly, we found no effect of mutations in
FAM46C, EGR1, LTB or ROBO1. Presence or absence of a
subclonal driver mutation did not influence clinical outcome
either. Interestingly, TP53 and SP140 mutations correlated
with shorter relapse-free survival, but both had no effect on
overall survival (Supplementary Fig. S6B,D,Bi,Di, respectively).
We then looked at the influence of the overall mutational
spectrum on survival. We found no difference in patients with
higher fraction of mutations generated by Signature B, or higher
fraction of subclonal mutations (Supplementary Fig. S6A,C,Ai,Ci,
respectively). Conversely, increased number of variants correlated
with a higher risk of relapse and death (Supplementary
Fig. S6E,Ei). Sample sizes here are clearly limited, and defining
the prognostic role of such variables will require considerably
larger cohorts.
Discussion
In this study, we report the largest myeloma cohort to date where
the coding exome of purified tumour cells was investigated by
NGS. The selection of patients in our study was somewhat
different to previously published reports, with overrepresentation
of advanced disease, hyperdiploid and del(17p) cases and
underrepresentation of t(11;14) and t(4:14). This may explain
the low frequency of DIS3 mutations (mostly found in IGH
rearranged cases so far5,7), and higher prevalence of TP53 and
FAM46C variants.
The depth of sequencing in our study was higher than the one
from other reports, and we validated every variant that was
reported by the initial whole-exome sequencing. This allowed for
the validation of numerous low burden variants, and provided
enough resolution to dissect the subclonal structure of the
tumours. We confirm previous reports showing subclonal KRAS,
NRAS and BRAF mutations in MM7 that we observe in about a
third of patients. This will be relevant in trials of MEK and BRAF
inhibitors, as their therapeutic effect should be maximal only in
cases where these driver mutations are present in all tumour
cells. We show for the first time concurrent BRAF and NRAS or
KRAS mutations at diagnosis in the same patient, another finding
that has therapeutic implications. BRAF inhibitors can have a
paradoxical ERK-activating effect in RAS-mutated cells, therefore
inducing secondary tumours driven by oncogenic RAS49,50. This
suggests that there may be paradoxical tumour-enhancing effects
of BRAF inhibitors in patients with coexistent BRAF and RAS
mutations. Furthermore, the presence of mutations of two genes
involved in the MAPK pathway in the same patient raises the
possibility that MM shows features of convergent evolution and
underscores the relevance of this pathway for MM pathogenesis,
but also the challenges to exploit it for therapeutic purposes.
Our large cohort allowed for a more comprehensive analysis of
recurrently mutated genes in MM compared with previous
studies, which resulted in novel findings. We confirm that
FAM46C is recurrently inactivated in MM in a pattern typical of a
tumour-suppressor gene, and associates with the hyperdiploid
subgroup of MM. We describe novel candidate tumour-
suppressor genes hit by recurrent inactivating mutations at a
significant rate, such as SP140 and LTB. Interestingly, SP140 is
expressed to high levels in plasma cells and linked to germline
susceptibility to CLL51. The germline risk allele is associated with
reduced expression of SP140 in lymphocytes51, which would be
consistent with the observations of truncating mutations here.
Furthermore, the increased risk of relapse associated with SP140
mutations in our cohort suggests this gene may have prognostic
features in MM. Another recurrently mutated gene, EGR1,
encodes a protein that acts downstream of the JUN pathway,
enacting an apoptosis programme in MM cells through
downregulation of survivin and upregulation of caspases52.
Knockdown of EGR1 in myeloma cells enhanced their
resistance to bortezomib52, and the clustered point mutation of
key residues that we observed may have similar effects.
We show that the heterogeneous subclonal structure and
mutational repertoire of MM samples is generated by at least two
mutational processes. The relative contribution of each process
changed over time or within subclones in most patients, and the
contribution of Signature B increased most markedly in the two
patients presenting with extramedullary relapse of MM and
showing distinct branching evolution. This suggests that the
ability to grow independently of the bone marrow microenviron-
ment is gained through substantial changes in the genome of the
neoplastic plasma cells. Nevertheless, we fail to demonstrate a
correlation between survival and either the prevalence of a
specific mutational signature, or the different levels of subclonal
complexity of each tumour. Rather, we show that cases with
significantly higher number of mutations had worse relapse-free
and overall survival, regardless of how mutations were generated
or distributed across subclones. In light of recent data showing
that the number of variants in MM correlates with stage of
disease8, our findings suggest that more advanced disease at
diagnosis negatively impacts the clinical outcome.
The presence of high variability in genomic architecture across
samples highlights the need for therapeutic interventions directed
at multiple targets rather than a single genomic anomaly, and
underscores the striking success of combination therapies with
proteasomal inhibitors and immunomodulatory agents53. As we
move towards an era of personalized therapy for myeloma and
other cancers, we need to build an understanding of the
recurrently mutated genes, their effect on drug response and
the impact of the admixture of subclones containing specific
mutations on initial presentation, therapy and relapse. The well-
established practice of serial bone marrow examination to
monitor disease status, the complexity of the genomic
landscape and the rapidly evolving therapeutic options suggests
MM is a powerful testbed for this vision.
Methods
Sequencing and genomic alignment. The study involved the use of human
samples, which were collected after written informed consent was obtained. Samples
and data were obtained and managed in accordance with the Declaration of Helsinki
under protocol 08/H0308/303: somatic molecular genetics of human cancers, Mela-
noma and Myeloma (Dana Farber Cancer Institute). The same protocol was approved
by RES Committee East of England—Cambridge Central.
We sequenced the protein-coding exome of 84 tumour samples from 67
patients with MM. DNA was isolated from CD138-positive myeloma cells purified
from bone marrow, and constitutional control DNA originated from peripheral
blood mononuclear cells. Purity of the CD138þ fraction was assessed by anti-
CD138 immunocytochemistry post sorting, and only samples with 490% plasma
cells were sequenced. Two (n¼ 13) or three (n¼ 2) serial samples were available
for 15 patients. Fifteen patients were sampled at disease relapse, including 14 with
serial samples, and 52 were sampled before treatment. Karyotype and/or FISH data
were available for all patients, and the Affymetrix Genome-Wide Human SNP
Array 6.0 (SNP6) was performed in 19/84 samples (Supplementary Table S1).
Genomic libraries enriched for protein-coding exons were generated by
hybridization to RNA baits from matched tumour and germline DNA samples, using
the Agilent SureSelect Human Exon Kit (Agilent, G3362)54. The libraries, containing
an average insert size of 200–300 bp, were analysed on the Illumina HiSeq2000
sequencing platform. Paired 75 bp sequencing reads were generated using the
standard protocol. Paired-end sequencing reads were aligned to the human genome
(NCBI build37) using the BWA algorithm55. Reads which were unmapped, PCR-
derived duplicates or outside the targeted region were excluded from analysis. The
remaining uniquely mapping reads provided an average of 75.38% coverage over the
targeted exons at a minimum depth of 30 (Supplementary Table S2).
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To identify somatically acquired coding point mutations, we used CaVEMan
(Cancer Variants through Expectation Maximization)23,54, an algorithm that uses a
naı¨ve Bayesian classifier to estimate the posterior probability of each possible
genotype (wild type, germline SNP, somatic mutation) at a given base, accounting
for the effects of observables such as base quality (measuring signal-to-noise ratio),
read position, sequencing lane and read orientation. CaVEMan is configured to
incorporate knowledge of copy number and normal cell contamination in the
posterior probability calculations. To call insertions and deletions, we used split-
read mapping implemented as a modification of the Pindel algorithm56. We
include in the search for indels read-pairs in which one or both ends map to the
genome, but allow one of the pair to have mismatches, insertions or deletions.
Pindel searches for reads where one end is anchored on the genome, and the other
end can be mapped with high confidence in two (split) portions, spanning a
putative indel.
All somatic coding mutations underwent validation regardless of their allelic
fraction. For a fraction of the variants (B25%), we used PCR followed by massively
parallel pyrosequencing (Roche 454)26. For the remainder, new libraries were
produced after whole-genome amplification, and variants were validated by
hybridization and pull-down with a custom bait set. The allelic fraction of variants
in the original whole-exome study (on native DNA) and that of the targeted pull-
down validation (on amplified DNA) were combined since they showed a near-
perfect correlation (r¼ 0.89, P¼o2.2e 16, Pearson’s product-moment
correlation), implying that whole-genome amplification did not introduce bias in
our data. In serial samples, each variant was validated in all samples from that
patient. For variants validated by Roche 454, coverage (B100 on average) and
allelic fraction data came from the original whole-exome study.
The sensitivity of our pipeline to detect a given subclonal mutation was
previously shown on whole-genome sequencing data to vary, and is especially
dependent on coverage across the mutated base and the extent of normal cell
contamination11. For our study, based on exome data, we sample less of the
genome but do so at higher depth. Thus, our sensitivity to detect at least a fraction
of the subclonal mutations was high, as evidenced by the fact that we robustly
detect and validate mutations down to 5–10% of tumour cells.
Copy-number analysis and fraction of mutated cells estimates. SNP array
hybridization on the Genome-Wide Human SNP Array 6.0 (Affymetrix) platform
was performed (Supplementary Table S1) according to the manufacturer protocols57
for 19 out of 84 samples of the exome screen. For the remaining 65 samples, copy-
number data were derived from exome-sequencing data.
Copy-number analysis was performed using ASCAT (version 2.2) taking into
account non-neoplastic cell infiltration and tumour aneuploidy and resulted in
integral allele-specific copy-number profiles for the tumour cells58. ASCAT output
was compared with karyotype/FISH analysis, where available, showing a highly
significant correlation: the P-value reflecting the correlation between ASCAT and
FISH analysis for hyperdiploidy, del(13) and del(17p) waso2.2e 16,o2.2e 16
and 3.615e 12, respectively (Fisher exact test). It was previously reported that
ASCAT can reliably identify clonal and subclonal copy-number changes in
tumours using SNP6 or whole-exome sequencing data26,58 and our data further
reinforce this evidence26,59. Homozygous deletions were called if there were zero
copies in the tumour cells.
The mutation copy number, nmut, equivalent to the fraction of tumour cells
carrying a given substitution multiplied by the number of chromosomal copies of
the mutation, nchr, was estimated as previously described26, using:
nmut ¼ fs 1r rn
t
locus þ nnlocusð1 rÞ
  ð1Þ
where fs is the fraction of mutated reads observed in the sequencing data, and r,
ntlocusand n
n
locusare respectively the tumour purity, the locus-specific copy number in
the tumour cells and the locus-specific copy number in the normal cells, inferred
from ASCAT. The confidence intervals for the mutation copy numbers were
generated by bootstrap resampling the wild-type and mutant reads at each mutated
locus (n¼ 10,000) and applying the above formula to the resampled fractions of
reads. The mutation copy number reflects the percentage of tumour cells carrying
the mutation, and allows comparison across samples with different karyotypes and
fraction of contaminating normal cells. Thus, heterozygous mutations occurring
at a diploid locus, and mutations occurring at a locus that underwent heterozygous
or subclonal deletion of the WT allele are assigned the same mutation copy
number. Note that indels were excluded from this analysis because of potential
mapping bias that would decrease the confidence in quantifying their allelic fraction.
Mutations that are present on multiple copies of a chromosome or chromosome
segment as a result of a copy-number aberration will have mutation copy numbers
above 1. In order to group mutations by the fraction of cells containing a mutation,
the number of chromosomes bearing a mutation, nchr, must be known. For all
mutations in amplified regions with major copy number C, the observed number
of mutant and wild-type reads was compared against the expected fs values
resulting from the mutation being present on 1, 2,yC chromosome copies,
assuming a binomial distribution, and nchr was assigned the value of C with the
maximum likelihood. The fraction of cells bearing each mutation was then
calculated as nmut/nchr.
1D and 2D variant clustering. The plots in Fig. 2b–d and Supplementary Fig. S1
were produced using a previously developed Bayesian Dirichlet process to model
clusters of clonal and subclonal point mutations, allowing inference of the number
of subclones and the fraction of cells within each subclone11. Within this model,
the number of reads bearing the ith mutation, yi, was drawn from a binomial
distribution
yi  Bin Ni; zipið Þ; with pi  DP aP0ð Þ ð2Þ
where Ni is the total number of reads at the mutated base and zi is the expected
fraction of reads that would report a mutation present in 100% of tumour cells at
that locus. pIA(0, 1), the fraction of tumour cells carrying the ith mutation, was
modelled as coming from a Dirichlet process DP, with concentration parameter a.
We used the stick-breaking representation of the Dirichlet process:
oh ¼ Vh
Y
loh
1Vlð Þ; with Vh  Beta 1; að Þ ð3Þ
where oh is the weight of the hth mutation cluster, that is, the proportion of all
somatic mutations specific to that cluster.
For those patients with multiple samples, this model was extended into two
dimensions, with the number of mutant reads obtained from a pair of samples
obtained at different time points, yi,1 and yi,2, modelled as independent binomial
distributions, each with an independent p drawn with a Dirichlet process from a
base distribution U(0,1).
yi;1  Bin Ni;1; zi;1pi;1
 
; with pi;1  DP aP0ð Þ ð4Þ
yi;2  Bin Ni;2; zi;2pi;2
 
; with pi;2  DP aP0ð Þ ð5Þ
for both the one-dimensional and two-dimensional models, Gibbs sampling was
used to estimate the posterior distribution of the parameters of interest,
implemented in R, version 2.11.1. The Markov chain was run for 10,000 iterations,
of which the first 2,000 were discarded. The median of the density was estimated
from ph, each weighted by the associated value of oh, using a univariate or bivariate
Gaussian kernel, implemented in the R libraries stats and KernSmooth, respectively.
The sensitivity of this approach in detecting clusters of subclonal mutations was
previously estimated11, and was found to be dependent on coverage, on the fraction
of contaminating normal cells and number of mutations within the subclone itself.
Mutational processes and signature analysis. Signatures of mutational
processes were analysed using the Wellcome Trust Sanger Institute mutational
signatures framework14.
Statistical analysis of recurrently mutated genes. We used a model-based
approach (frequentist likelihood ratio tests) to classify genes based on their
observed patterns of recurrent mutation, based on ref. 60. In this method, the
expected number of non-synonymous mutations in a given gene is modelled as a
product of the number of vulnerable sites, the mutation rate of each type of
substitution and a separate selection coefficient for each gene and each type of non-
synonymous substitution. This allows quantifying selection at gene level avoiding
the confounding effects of gene length, sequence composition and different rates of
each substitution type.
We used a likelihood implementation of this model to evaluate whether the
frequency of missense, nonsense, splice-site substitutions and indels is higher than
expected by chance. Twelve parameters were used to model the 12 possible single
nucleotide substitutions and two additional parameters control for the CpG effect
on C4T transitions in each strand. Three selection parameters (wmis, wnon and
wsplice) quantified selection at missense, nonsense and essential splice-site
substitutions, respectively. Maximum likelihood was used to estimate these
parameters and likelihood ratio tests were used to test deviations from neutrality
(wmis¼ 1, wnon¼ 1 or wsplice¼ 1). Since the limited number of mutations per gene
prevents the estimation of different rates per gene, mutation rates were assumed
constant among genes and only the three selection parameters were allowed to
vary, thus reflecting a ratio between the observed and the expected numbers of
missense, nonsense, splice-site substitutions and indels per gene. Nevertheless, an
additional likelihood ratio test was performed to identify those genes whose
number of synonymous mutations significantly deviates from the assumed uniform
mutation rate. This analysis identified CCND1 as the only gene with a significantly
higher background mutation rate in the data set. For indels, a P-value was obtained
for each gene comparing the observed number of indels to the expected number
(estimated as the product of the CDS length and the exome wide average indel rate
per bp) using a cumulative Poisson distribution. For each gene, the four P-values
for indels, missense, nonsense and splice-site mutations were combined using
Fisher method. P-values were adjusted for multiple testing using Benjamini–
Hochberg FDR.
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